|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
global cancer statistics? Cancer Commun (Lond).
39(22)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bano N, Najam R, Qazi F and Mateen A:
Clinical features of oxaliplatin induced hypersensitivity reactions
and therapeutic approaches. Asian Pac J Cancer Prev. 17:1637–1641.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu T, Zhang X, Du L, Wang Y, Liu X, Tian
H, Wang L, Li P, Zhao Y, Duan W, et al: Exosome-transmitted
miR-128-3p increase chemosensitivity of oxaliplatin-resistant
colorectal cancer. Mol Cancer. 18(43)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wongsirisin P, Limpakan Yamada S,
Yodkeeree S, Punfa W and Limtrakul P: Association of DNA repair and
drug transporter in relation to chemosensitivity in primary culture
of thai gastric cancer patients. Biol Pharm Bull. 41:360–367.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Herraez E, Sanchez-Vicente L, Macias RIR,
Briz O and Marin JJG: Usefulness of the MRP2 promoter to overcome
the chemoresistance of gastrointestinal and liver tumors by
enhancing the expression of the drug transporter OATP1B1.
Oncotarget. 8:34617–34629. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Burger H, Zoumaro-Djayoon A, Boersma AW,
Helleman J, Berns EM, Mathijssen RH, Loos WJ and Wiemer EA:
Differential transport of platinum compounds by the human organic
cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 159:898–908.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tatsumi S, Matsuoka H, Hashimoto Y, Hatta
K, Maeda K and Kamoshida S: Organic cation transporter 2 and tumor
budding as independent prognostic factors in metastatic colorectal
cancer patients treated with oxaliplatin-based chemotherapy. Int J
Clin Exp Pathol. 7:204–212. 2013.PubMed/NCBI
|
|
11
|
Pelis RM, Suhre WM and Wright SH:
Functional influence of N-glycosylation in OCT2-mediated
tetraethylammonium transport. Am J Physiol Renal Physiol.
290:F1118–F1126. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Taniguchi N and Kizuka Y: Glycans and
cancer: Role of N-glycans in cancer biomarker, progression and
metastasis, and therapeutics. Adv Cancer Res. 126:11–51.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kleene R and Berger EG: The molecular and
cell biology of glycosyltransferases. Biochim Biophys Acta.
1154:283–325. 1993.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kudo T, Nakagawa H, Takahashi M, Hamaguchi
J, Kamiyama N, Yokoo H, Nakanishi K, Nakagawa T, Kamiyama T,
Deguchi K, et al: N-glycan alterations are associated with drug
resistance in human hepatocellular carcinoma. Mol Cancer.
6(32)2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lattova E, Tomanek B, Bartusik D and
Perreault H: N-glycomic changes in human breast carcinoma MCF-7 and
T-lymphoblastoid cells after treatment with herceptin and
herceptin/Lipoplex. J Proteome Res. 9:1533–1540. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tang Y, Cong X, Wang S, Fang S, Dong X,
Yuan Y and Fan J: GnT-V promotes chemosensitivity to gemcitabine in
bladder cancer cells through β1,6 GlcNAc branch modification of
human equilibrative nucleoside transporter 1. Biochem Biophys Res
Commun. 503:3142–3148. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li P, Zhang X, Wang H, Wang L, Liu T, Du
L, Yang Y and Wang C: MALAT1 is associated with poor response to
oxaliplatin-based chemotherapy in colorectal cancer patients and
promotes chemoresistance through EZH2. Mol Cancer Ther. 16:739–751.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhu Y, Meng Q, Wang C, Liu Q, Sun H, Kaku
T and Liu K: Organic anion transporters involved in the excretion
of bestatin in the kidney. Peptides. 33:265–271. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sprowl JA, van Doorn L, Hu S, van Gerven
L, de Bruijn P, Li L, Gibson AA, Mathijssen RH and Sparreboom A:
Conjunctive therapy of cisplatin with the OCT2 inhibitor
cimetidine: Influence on antitumor efficacy and systemic clearance.
Clin Pharmacol Ther. 94:585–592. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pan G, Li T, Zeng Q, Wang X and Zhu Y:
Alisol F 24 acetate enhances chemosensitivity and apoptosis of
MCF-7/DOX cells by inhibiting P-glycoprotein-mediated drug efflux.
Molecules. 21(183)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Morad SAF, Davis TS, MacDougall MR, Tan
SF, Feith DJ, Desai DH, Amin SG, Kester M, Loughran TP Jr and Cabot
MC: Role of P-glycoprotein inhibitors in ceramide-based
therapeutics for treatment of cancer. Biochem Pharmacol. 130:21–33.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Uemura T, Ito S, Ohta Y, Tachikawa M, Wada
T, Terasaki T and Ohtsuki S: Abnormal N-glycosylation of a novel
missense creatine transporter mutant, G561R, associated with
cerebral creatine deficiency syndromes alters transporter activity
and localization. Biol Pharm Bull. 40:49–55. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kazuaki O and Marth JD: Glycosylation in
cellular mechanisms of health and disease. Cell. 126:855–867.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Eichler J: Protein glycosylation. Curr
Biol. 29:R229–R231. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Varki A: Biological roles of glycans.
Glycobiology. 27:3–49. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nakahara S, Miyoshi E, Noda K, Ihara S, Gu
J, Honke K, Inohara H, Kubo T and Taniguchi N: Involvement of
oligosaccharide changes in alpha5beta1 integrin in a
cisplatin-resistant human squamous cell carcinoma cell line. Mol
Cancer Ther. 2:1207–1214. 2003.PubMed/NCBI
|
|
29
|
Lattová E, Bartusik D, Spicer V, Jellusova
J, Perreault H and Tomanek B: Alterations in glycopeptides
associated with herceptin treatment of human breast carcinoma mcf-7
and T-lymphoblastoid cells. Mol Cell Proteomics.
10(M111.007765)2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wojtowicz K, Januchowski R, Nowicki M and
Zabel M: Inhibition of protein glycosylation reverses the MDR
phenotype of cancer cell lines. Biomed Pharmacother. 74:49–56.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xue L, Williamson A, Gaines S, Andolfi C,
Paul-Olson T, Neerukonda A, Steinhagen E, Smith R, Cannon LM,
Polite B, et al: An update on colorectal cancer. Curr Probl Surg.
55:76–116. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kalayda GV, Kullmann M, Galanski M and
Gollos S: A fluorescent oxaliplatin derivative for investigation of
oxaliplatin resistance using imaging techniques. J Biol Inorg Chem.
22:1295–1304. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Meads MB, Gatenby RA and Dalton WS:
Environment-mediated drug resistance: A major contributor to
minimal residual disease. Nat Rev Cancer. 9:665–674.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Sanchez-Pupo RE, Johnston D and Penuela S:
N-glycosylation regulates pannexin 2 localization but is not
required for interacting with pannexin 1. Int J Mol Sci.
19(1837)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Srinivasan S, Romagnoli M, Bohm A and
Sonenshein GE: N-glycosylation regulates ADAM8 processing and
activation. J Biol Chem. 289:33676–33688. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cui J, Huang W, Wu B, Jin J, Jing L, Shi
WP, Liu ZY, Yuan L, Luo D, Li L, et al: N-glycosylation by
N-acetylglucosaminyltrans-ferase V enhances the interaction of
CD147/basigin with integrin β1 and promotes HCC metastasis. J
Pathol. 245:41–52. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang X, Li J and Geng M:
N-acetylglucosaminyltransferase V modifies TrKA protein, regulates
the receptor function. Cell Mol Neurobiol. 28:663–670.
2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang S, Lovejoy KS, Shima JE, Lagpacan
LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, et al:
Organic cation transporters are determinants of oxaliplatin
cytotoxicity. Cancer Res. 66:8847–8857. 2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sprowl JA, Ciarimboli G, Lancaster CS,
Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF
and Sparreboom A: Oxaliplatin-induced neurotoxicity is dependent on
the organic cation transporter OCT2. Proc Natl Acad Sci USA.
110:11199–11204. 2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
French JA: P-glycoprotein expression and
antiepileptic drug resistance. Lancet Neurol. 12:732–733.
2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Bergman AM, Pinedo HM, Talianidis I,
Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased
sensitivity to gemcitabine of P-glycoprotein and multidrug
resistance-associated protein-overexpressing human cancer cell
lines. Br J Cancer. 88:1963–1970. 2003.PubMed/NCBI View Article : Google Scholar
|
